The 10-second takeaway
For the quarter ended Dec. 31 (Q4), MEDNAX met expectations on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share expanded.
Margins dropped across the board.
MEDNAX booked revenue of $471.3 million. The 14 analysts polled by S&P Capital IQ predicted revenue of $473.7 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $404.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.32. The 15 earnings estimates compiled by S&P Capital IQ anticipated $1.30 per share. GAAP EPS of $1.32 for Q4 were 11% higher than the prior-year quarter's $1.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 34.2%, 590 basis points worse than the prior-year quarter. Operating margin was 21.9%, 70 basis points worse than the prior-year quarter. Net margin was 14.0%, 40 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $504.2 million. On the bottom line, the average EPS estimate is $1.15.
Next year's average estimate for revenue is $2.12 billion. The average EPS estimate is $5.55.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 174 members out of 181 rating the stock outperform, and seven members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 59 give MEDNAX a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $83.75.
Is MEDNAX the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add MEDNAX to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.